Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2008

Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123(12):2824-31.

Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, Jansen R, et al. Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center. Proc Natl Acad Sci U S A. 2008;105(39):14820-5.

Alsharif M, Aslan DL, Jessurun J, H Gulbahce E, Pambuccian SE. Cytologic diagnosis of metastatic seminoma to the prostate and urinary bladder: a case report. Diagn Cytopathol. 2008;36(10):734-8.

Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-17.

Cellini C, Hoda SA, Spigland N. Lupus-associated vasculitis manifesting as acute appendicitis in a 16 year old girl. Pediatr Rheumatol Online J. 2008;6:10.

Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J. 2008;27(16):2181-93.

Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2008;295(5):F1545-53.

Siscovick JR, Zapolanski T, Magro C, Carrington K, Prograis S, Nussbaum M, et al. Polypodium leucotomos inhibits ultraviolet B radiation-induced immunosuppression. Photodermatol Photoimmunol Photomed. 2008;24(3):134-41.

Arora N, Scognamiglio T, Zhu B, Fahey TJ. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg. 2008;32(7):1237-46.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765-75.